Results 111 to 120 of about 327,068 (394)

Concentrations of Cysteinyl Leukotrienes in Various Biological Fluids of Children with Bronchial Asthma, Atopic Dermatitis and Food Protein Induced Enterocolitis [PDF]

open access: yes, 2019
Clinical manifestation of food allergy is characterized by polymorphic cutaneous, respiratory and gastrointestinal syndromes. Leukotrienes occupy a key place in the pathogenesis of a wide range of inflammatory diseases, including bronchial asthma ...
Haiduchyk, H. (Halyna)   +1 more
core   +4 more sources

Role of mepolizumab in severe allergic asthma with vocal cord polyp

open access: yesLung India, 2022
Interleukin (IL)-5 plays an important role in development, recruitment, and survival of eosinophils, thereby causing debilitating signs and symptoms associated with severe eosinophilic asthma.
Azmat Karim   +2 more
doaj   +1 more source

COVID-19 diagnosis by routine blood tests using machine learning [PDF]

open access: yes, 2020
Physicians taking care of patients with coronavirus disease (COVID-19) have described different changes in routine blood parameters. However, these changes, hinder them from performing COVID-19 diagnosis. We constructed a machine learning predictive model for COVID-19 diagnosis.
arxiv   +1 more source

Emerging Biological Therapies in Severe Eosinophilic Asthma [PDF]

open access: yesPulmonary Therapy, 2016
A small fraction of patients with asthma have severe, persistent disease that is often refractory to standard therapy. To meet this need, a growing emphasis has been placed on the development of alternative, novel therapies and the ability to characterize those patients who are most likely to benefit from these therapies.
Bryan R. Hay   +2 more
openaire   +1 more source

Deficiency of DEK proto‐oncogene alleviates allergic rhinitis by inhibiting RhoA/Ezrin‐mediated mitochondrial fission

open access: yesAnimal Models and Experimental Medicine, EarlyView.
Schematic diagram of the mechanism of DEK regulating RhoA activation Ezrin. Upon house dust mite (HDM) stimulation, HDM‐specific immunoglobulin E (IgE) and inflammatory factors such as interleukin 4 (IL‐4), IL‐5, IL‐13, and eosinophils increased in the nasal mucosa.
Longzhu Dai   +8 more
wiley   +1 more source

Chronic rhinosinusitis with nasal polyps in older adults : clinical presentation, pathophysiology, and comorbidity

open access: yes, 2019
Purpose of Review Chronic rhinosinusitis and nasal polyps (CRSwNP) is a common condition that significantly affects patients' life. This work aims to provide an up-to-date overview of CRSwNP in older adults, focusing on its aging-related clinical ...
Bachert, Claus   +3 more
core   +2 more sources

Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma

open access: yesEuropean Respiratory Journal
Graphical abstract Overview of the study. OCS: oral corticosteroid; ACQ-5: Asthma Control Questionnaire (5-item); FEV1: forced expiratory volume in 1 s. Background Patients with severe eosinophilic asthma, characterised by a high disease burden, benefit ...
Yuto Hamada   +11 more
semanticscholar   +1 more source

Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics

open access: yesRespiratory Research, 2021
Background The OSMO study assessed the efficacy of switching to mepolizumab in patients with severe eosinophilic asthma that was uncontrolled whilst receiving omalizumab.
M. Liu   +11 more
semanticscholar   +1 more source

Benralizumab for the treatment of severe eosinophilic asthma [PDF]

open access: yesPrescriber, 2018
Benralizumab (Fasenra) is a new anti‐interleukin‐5 monoclonal antibody therapy for the management of severe uncontrolled eosinophilic asthma. This article discusses its properties, clinical trial efficacy and adverse effects.
openaire   +2 more sources

Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, relapsing, inflammatory disease. Management of EGPA predominantly relies on oral corticosteroids (OCS), which are associated with many adverse effects. The phase 3 MIRRA trial demonstrated efficacy and safety of mepolizumab, anti‐interleukin‐5 biologic, for EGPA.
Michael E. Wechsler   +34 more
wiley   +1 more source

Home - About - Disclaimer - Privacy